Last Updated : September 7, 2018
Details
FilesGeneric Name:
Tolvaptan
Project Status:
Complete
Therapeutic Area:
Autosomal dominant polycystic kidney disease
Manufacturer:
Otsuka Canada Pharmaceutical Inc.
Call for patient/clinician input open:
Brand Name:
Jinarc
Project Line:
Reimbursement Review
Project Number:
SR0435-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Submission Type:
Initial
Indications:
Autosomal dominant polycystic kidney disease (ADPKD)
Recommendation Type:
Do not list
Final Recommendation:
Files
Last Updated : September 7, 2018